Loading clinical trials...
Loading clinical trials...
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients with Autoimmune Hemolytic Anemia Have Failed ≥ 3 Lines of Therapy
Conditions
Interventions
universal allogeneic anti-CD19/BCMA CAR T-cells
Locations
1
China
Regenerative Medicine Center and Red Blood Cell Disorders Center
Tianjin, Tianjin Municipality, China
Start Date
December 5, 2024
Primary Completion Date
February 5, 2026
Completion Date
December 5, 2026
Last Updated
December 13, 2024
NCT04645199
NCT07361094
NCT07175493
NCT06888960
NCT06921980
NCT04005638
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions